JCF Intersections

The OA journal exploring heart failure and its intersection with different fields of medicine. Find out more:

[JCF Intersections @JCFINT]

🔗 https://t.co/EQKFNeuQa2

[JCF Intersections @JCFINT]

Anthracycline cardiotoxicity remains a major challenge in cardio-oncology.

This meta-analysis suggests SGLT2i may reduce mortality, HF events, & arrhythmias in anthracycline-treated patients, with reassuring safety signals.

A promising prevention strategy? 🫀

Link below 👇

[JCF Intersections @JCFINT]

New month. New conversations in heart failure.

The May issue of JCF-Intersections is out now featuring fresh insights, expert perspectives, and meaningful discussion from across the field.

https://t.co/c5PZ2ZGvyb

[JCF Intersections @JCFINT]

🔗 https://t.co/CRgF5T5Xzb

[JCF Intersections @JCFINT]

Should cardiogenic shock teams become the standard of care? It's up for debate!🫀

One viewpoint argues yes: multidisciplinary shock teams can streamline diagnosis, coordinate care & improve outcomes across institutions. Observational data support their impact.

🧵👇

[JCF Intersections @JCFINT]

Another view urges caution: CS care is time-sensitive, & assembling teams could delay treatment. Clear, evidence-based protocols may be just as important as the team itself.

The future likely lies in combining structured pathways with multidisciplinary care.⚖️

🧵👇

[JCF Intersections @JCFINT]

tMCS (e.g., VA-ECMO) can save lives—but what if there’s no path forward?

A new perspective examines the ethical challenge of the “bridge to nowhere” and explores concepts like dynamic consent, moral distress, distributive justice, and so much more⚖️🫀

🔗 https://t.co/xuISKfaiKd

[JCF Intersections @JCFINT]

LVAD offers a stable platform to help patients overcome barriers to heart transplant.

In one cohort, ~70% had modifiable barriers and 60% of these resolved at least one after LVAD, highlighting the role of multidisciplinary care.🫀📊

🔗 https://t.co/bVvqLEBzyR

[JCF Intersections @JCFINT]

Cardiogenic shock → low CO & end-organ hypoperfusion.

LV failure is common, but don’t miss other causes: valvular disease, mechanical MI complications, or RV failure.

A systematic approach + bedside echo can rapidly guide diagnosis and escalation.🫀

🔗 https://t.co/byjKximAD9

[JCF Intersections @JCFINT]

JCF Intersections is out now!

Where research meets perspective, and new ideas take shape across disciplines.

Explore the latest 👉 https://t.co/c5PZ2ZGvyb

#HeartFailure #Cardiology

[JCF Intersections @JCFINT]

@noshreza @JasonKatzMD @SarahChuzi @JulieDoberne @ShahzebKhanMD @ElliottMillerMD @hcg_md @dranulala @robmentz 🔗 https://t.co/yNamrrHklm

[JCF Intersections @JCFINT]

A HFrEF polypill💊 could ⬆️ GDMT uptake, but prescriber prefs are unknown. Using a 5-stage mixed-methods process, researchers built a discrete choice experiment to test cardiologists’ prefs—work that will directly inform future HFrEF polypill clinical trials.

Read more 👇

[JCF Intersections @JCFINT]

New science 🚨!

In an analysis of centrifugal-flow LVAD trials, digoxin💊 users showed greater improvement in 6MWT 🚶 vs no digoxin (especially in older pts) with similar QOL & AE rates. Digoxin was also linked to better 4-yr survival in NICM pts.

🔗 https://t.co/ize88ecsRp

[JCF Intersections @JCFINT]

📣 Last chance to register for JCF-I Office Hours!

Join Editor in Chief Dr. Katz and Deputy Editor Dr. Reza to answer your questions on:
✅ JCF-I's upcoming publications
✅ What they are looking for in submissions
✅ Updates on the year ahead

https://t.co/UWaKPHd0rF

[JCF Intersections @JCFINT]

The January issue of JCF-I is now available 👉 bringing forward new evidence, perspectives, and conversations in heart failure + various intersections.

Read the full issue 📖https://t.co/c5PZ2ZGvyb

[JCF Intersections @JCFINT]

Time is running out! Register for JCF-I Office Hours⌛

Join Editor in Chief Dr. Katz and Deputy Editor Dr. Reza to answer your questions on:
✅ JCF-I's upcoming publications
✅ What they are looking for in submissions
✅ Updates on the year ahead

https://t.co/UWaKPHd0rF

[JCF Intersections @JCFINT]

🚨 JCF-I Office Hours

Join Editor in Chief Dr. Katz and Deputy Editor Dr. Reza to answer your questions on:
✅ JCF-I's upcoming publications
✅ What they are looking for in submissions
✅ Updates on the year ahead

Register: https://t.co/UWaKPHdyhd

[JCF Intersections @JCFINT]

Overall, meaningful weight loss and potential cardiac benefits.

Read more 👉 https://t.co/QxQoTxHHDs

[JCF Intersections @JCFINT]

📢 New study in JCF-I on the safety and effectiveness of a low-carbohydrate ketogenic diet LCKD for weight loss in patients with overweight/obesity and HF.

This is one of the largest real-world looks at LCKD use in HF. 🫀🍽️

See below ⬇️
https://t.co/QxQoTxHHDs

[JCF Intersections @JCFINT]

🍽️ Key Highlights
-125 overweight/obese HF patients Rx LCKD were followed for avg 2 years
-Median weight loss: 11.2 kg (p<0.01)
-No ⬇️ in EF
-Significant ⬇️ in HF 🏥 in HFpEF, numerically lower in HFrEF
-LCKD was safe, with improvements in several metabolic markers